A multicenter, randomized controlled, open-label phase II clinical study of the efficacy and safety of evoximab (AK112) combined with nab-paclitaxel versus nab-paclitaxel in second-line patients with extensive-stage small cell lung cancer

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2024
This article has no abstract
Epistemonikos ID: 3c96b63abd889e234e4d6e4ffb41b2a8b813d415
First added on: Apr 08, 2025